Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$30.43 - $56.65 $1,217 - $2,266
-40 Closed
0 $0
Q2 2018

Aug 22, 2018

SELL
$46.25 - $104.45 $21,737 - $49,091
-470 Reduced 92.16%
40 $2,000
Q1 2018

Jun 25, 2018

BUY
$57.4 - $108.44 $29,274 - $55,304
510 New
510 $54,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Mount Yale Investment Advisors, LLC Portfolio

Follow Mount Yale Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mount Yale Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mount Yale Investment Advisors, LLC with notifications on news.